| Code | CSB-RA025141MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Solrikitug, designed to target thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that plays a critical role in initiating and amplifying type 2 inflammatory responses. TSLP is produced by epithelial cells in response to various triggers including allergens, pathogens, and mechanical injury, and acts on multiple immune cell types including dendritic cells, T cells, mast cells, and innate lymphoid cells. Elevated TSLP expression has been implicated in the pathogenesis of allergic diseases such as asthma, atopic dermatitis, chronic rhinosinusitis, and eosinophilic esophagitis, making it an important therapeutic target for type 2 inflammatory conditions.
Solrikitug is a human monoclonal antibody that binds to TSLP and prevents its interaction with the TSLP receptor complex, thereby blocking downstream inflammatory signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating TSLP-mediated immune mechanisms, studying type 2 inflammation pathways, and exploring potential therapeutic interventions for allergic and inflammatory disorders in preclinical models.
There are currently no reviews for this product.